[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337096-105":59,"doc-detail-337096-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pd-1-blockade-plus-cisplatin-based-chemotherapy-in-patients-with-small-cellneuroendocrine-bladder-and-prostate-cancers","PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers","","Gu et al. investigate immunologic mechanisms underlying clinical responses to PD-1 blockade combined with cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers. Using single-cell sequencing of serial peripheral blood mononuclear cells, the study identifies highly expanded CD8+ T cell clonotypes with conserved gene signatures. The expansion of these clonotypes is reported to correlate with progression-free survival. A phase 1b cohort shows promising overall response and tolerable safety with biomarker-linked clonal T cell repertoire dynamics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pd-1-blockade-plus-cisplatin-based-chemotherapy-in-patients-with-small-cellneuroendocrine-bladder-and-prostate-cancers/337096/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pd-1-blockade-plus-cisplatin-based-chemotherapy-in-patients-with-small-cellneuroendocrine-bladder-and-prostate-cancers/337096.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment combination is studied in this article?","Question",{"text":112,"@type":113},"The study evaluates PD-1 blockade with pembrolizumab combined with cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the study investigate immune responses?",{"text":117,"@type":113},"It uses single-cell sequencing and T cell receptor sequencing of serial peripheral blood samples to characterize T cell clonal expansion over treatment.",{"name":119,"@type":110,"acceptedAnswer":120},"What biomarker relationship is reported?",{"text":121,"@type":113},"Highly expanded CD8+ T cell clonotypes show conserved gene signatures, and clonal expansion correlates with progression-free survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337096,1790957284,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Article  \nPD-1 blockade plus cisplatin-based chemotherapy inpatients with small cell/neuroendocrine bladder and prostate cancers  \nAuthors  \nYiqian Gu, Ann Ly, Sara Rodriguez, ..., Alexandra Drakaki, Matthew B. Rettig, Arnold I. Chin  \nCorrespondence  \n[arnoldchin@mednet.ucla.edu](arnoldchin@mednet.ucla.edu)  \nIn brief  \nGu et al. examine the immunologic basis for clinical responses through single-cell sequencing of serial PBMCs in patients with small cell/neuroendocrine cancers. They show that highly expanded CD8+ T cell clonotypes exhibit a conserved gene signature whose expansion correlates with progression-free survival.  \nd Pembrolizumab and chemotherapy show positive efﬁcacy signals  \nd Subset of CD8+ T cells persist and expand over treatment  \nd Highly expanded CD8+ T cells exhibit conserved gene signatures over time  \nd Clonal expansion of T cell repertoire correlates with progression-free survival  \nGu et al., 2024, Cell Reports Medicine 5, 101824  \nNovember 19, 2024 ª 2024 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2024.101824](https://doi.org/10.1016/j.xcrm.2024.101824)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nPD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers  \nYiqian Gu,1,9,12 Ann Ly,2,10,12 Sara Rodriguez,2 Hanwei Zhang,2 Jiyoon Kim,3 Zhiyuan Mao,4 Ankush Sachdeva,2 Nazy Zomorodian,2 Matteo Pellegrini,1,5,6 Gang Li,3,5 Sandy Liu,7,11 Alexandra Drakaki,5,7 Matthew B. Rettig,5,7,8 and Arnold I. Chin2,5,6,13,*  \n1Department of Molecular, Cellular and Developmental Biology, University of California, Los Angeles, Los Angeles, CA, USA  \n2Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA  \n3Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA  \n4Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, USA  \n5Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA  \n6Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, USA  \n7Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA  \n8The VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA  \n9Present address: Bioinformatics Interdepartmental Program, University of California Los Angeles, Los Angeles, CA, USA  \n10Present address: School of Medicine, University of California Davis, Sacramento, CA, USA  \n11Present address: Department of Medicine, Division of Hematology and Oncology, City of Hope, Irvine, CA, USA  \n12These authors contributed equally  \n13Lead contact  \n*Correspondence: [arnoldchin@mednet.ucla.edu](arnoldchin@mednet.ucla.edu)[ ](arnoldchin@mednet.ucla.edu)[https://doi.org/10.1016/j.xcrm.2024.101824](https://doi.org/10.1016/j.xcrm.2024.101824)  \nSUMMARY  \nSmall cell neuroendocrine cancers share biologic similarities across tissue types, including transient response to platinum-based chemotherapy with rapid progression of disease. We report a phase 1b study of pembrolizumab in combination with platinum-based chemotherapy in 15 patients with stage III-IV small cell bladder (cohort 1) or small cell/neuroendocrine prostate cancers (cohort 2) . Overall response rate (ORR) is 43% with two-year overall survival (OS) rate of 86%(95% conﬁdence interval [CI]: 0.63, 1.00) for cohort 1 and 57%(95% CI: 0.30, 1.00) for cohort 2 . Treatment is tolerated well with grade 3 or higher adverse events occurring in 40% of patients with no deaths or treatment cessation secondary to toxicity. Single-cell and T cell receptor sequencing of serial peripheral blood samples reveals clonal expansion of diverse T cell repertoire correlating wit","cbCaigSNh0Wu4Diw","https://ap.wps.com/l/cbCaigSNh0Wu4Diw","pdf",5390125,"English","# Summary\n# Introduction\n# Results and clinical outcomes\n## Safety and adverse events\n## Efficacy and survival measures","[{\"question\":\"What treatment combination is studied in this article?\",\"answer\":\"The study evaluates PD-1 blockade with pembrolizumab combined with cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers.\"},{\"question\":\"How does the study investigate immune responses?\",\"answer\":\"It uses single-cell sequencing and T cell receptor sequencing of serial peripheral blood samples to characterize T cell clonal expansion over treatment.\"},{\"question\":\"What biomarker relationship is reported?\",\"answer\":\"Highly expanded CD8+ T cell clonotypes show conserved gene signatures, and clonal expansion correlates with progression-free survival.\"}]","PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers | PDF",1790017669,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79cb89a3c5e019f0a7fc7027f1c27c59.webp",983,1276,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfadaa976e932d5503b10ee8a14d9fee.webp",982,1275,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/384c4751b9a7f61b96e36a5398836f52.webp",981,1273,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5b213b76f7dccfb84c3b08045176040.webp",980,1272]